PolyPeptide

Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide

Samsung Biologics plans a $1.8 billion cash acquisition of Swiss drugmaker PolyPeptide to expand capabilities in peptide-based therapeutics like GLP-1 drugs. The offer includes a 6.1% premium and aims